Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications
- PMID: 16569797
- DOI: 10.1345/aph.1G617
Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications
Abstract
Background: The distinct absorption characteristics of the conventional enteric-coated, delayed-release (DR) and the novel extended-release (ER) divalproex sodium formulations are not well recognized.
Objective: To quantitatively and qualitatively differentiate the absorption characteristics of divalproex-DR and -ER formulations.
Methods: Healthy volunteers (N = 28) received single 1000 mg doses of divalproex-DR and divalproex-ER tablets in a crossover fashion. Noncompartmental and compartmental analyses were used to estimate valproic acid (VPA) pharmacokinetics from the plasma concentration-time profiles determined from intensive blood sampling over 48 hours.
Results: VPA was not absorbed from divalproex-DR in the first 2 hours (absorption lag-time) after dosing. After VPA release in the intestine, approximately 63% of the dose was absorbed in less than 1 hour, that is, 2.9 hours (mean absorption time) from dosing. Maximum concentration (C(max)) was achieved approximately 4 hours after dosing. VPA absorption was complete ( approximately 93% of dose) within 3 absorption half-lives ( approximately 4.5 h) post-absorption lag-time, that is, 6-7 hours from dosing. In contrast, VPA absorption from divalproex-ER starts immediately after administration, initially at a modest rate, followed by slow and extended absorption at a constant rate for more than 20 hours; VPA concentrations at 1 and 2 hours were 28% and 40% of C(max). Approximately 53% of the dose was absorbed within 12 hours (mean absorption time); complete absorption occurred over more than 20 hours without any dose dumping.
Conclusions: VPA absorption from enteric-coated divalproex-DR is rapid following a lag-time of approximately 2 hours and is complete within 6-7 hours of dosing. In contrast, VPA absorption from divalproex-ER starts immediately after administration, but occurs at a slow, approximately constant rate over more than 20 hours.
Similar articles
-
Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials.Front Pharmacol. 2022 Apr 5;13:811017. doi: 10.3389/fphar.2022.811017. eCollection 2022. Front Pharmacol. 2022. PMID: 35479307 Free PMC article.
-
Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.J Clin Pharmacol. 2004 Jul;44(7):737-42. doi: 10.1177/0091270004266782. J Clin Pharmacol. 2004. PMID: 15199078 Clinical Trial.
-
Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.Epilepsy Res. 2007 Mar;73(3):275-83. doi: 10.1016/j.eplepsyres.2006.11.005. Epub 2007 Jan 8. Epilepsy Res. 2007. PMID: 17208410
-
Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.Epilepsy Res. 2009 Dec;87(2-3):260-7. doi: 10.1016/j.eplepsyres.2009.09.015. Epub 2009 Nov 4. Epilepsy Res. 2009. PMID: 19892524
-
Bioequivalence in development of antiepileptic drugs.Epilepsy Res. 2006 Jan;68(1):82-5. doi: 10.1016/j.eplepsyres.2005.09.033. Epilepsy Res. 2006. PMID: 16377144 Review.
Cited by
-
Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.CNS Drugs. 2017 May;31(5):389-403. doi: 10.1007/s40263-017-0430-3. CNS Drugs. 2017. PMID: 28405886 Review.
-
Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials.Front Pharmacol. 2022 Apr 5;13:811017. doi: 10.3389/fphar.2022.811017. eCollection 2022. Front Pharmacol. 2022. PMID: 35479307 Free PMC article.
-
Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation.J Pharmacokinet Pharmacodyn. 2011 Jun;38(3):369-83. doi: 10.1007/s10928-011-9198-0. Epub 2011 Apr 16. J Pharmacokinet Pharmacodyn. 2011. PMID: 21499748 Free PMC article.
-
Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia.Clin Pharmacokinet. 2024 Oct;63(10):1435-1448. doi: 10.1007/s40262-024-01418-8. Epub 2024 Sep 19. Clin Pharmacokinet. 2024. PMID: 39298079
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources